Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Significance: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Citing Articles

A Single-Institution Retrospective Series of SARS-CoV-2 Infection in Adult Glioma Patients.

Lanman T, Ruiz A, Nagpal S Case Rep Oncol. 2023; 16(1):980-987.

PMID: 37900820 PMC: 10601729. DOI: 10.1159/000531836.

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

Johnson D, Atkins M, Hennessy C, Wise-Draper T, Heilman H, Awosika J BMC Cancer. 2023; 23(1):265.

PMID: 36949413 PMC: 10033295. DOI: 10.1186/s12885-023-10708-6.

Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.

Azar J, Evans J, Sikorski M, Chakravarthy K, McKenney S, Carmody I JCI Insight. 2023; 8(6).

PMID: 36749632 PMC: 10070099. DOI: 10.1172/jci.insight.163434.

Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders.

Saade E, Hojat L, Gundelly P, Salata R Best Pract Res Clin Haematol. 2022; 35(3):101375.

PMID: 36494144 PMC: 9398935. DOI: 10.1016/j.beha.2022.101375.

Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era.

Della Pia A, Zhao C, Jandir P, Gupta A, Batistick M, Kim G Cancers (Basel). 2022; 14(17).

PMID: 36077782 PMC: 9454633. DOI: 10.3390/cancers14174252.

References

Anolik J, Friedberg J, Zheng B, Barnard J, Owen T, Cushing E . B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2006; 122(2):139-45. DOI: 10.1016/j.clim.2006.08.009. View

Grivas P, Khaki A, Wise-Draper T, French B, Hennessy C, Hsu C . Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021; 32(6):787-800. PMC: 7972830. DOI: 10.1016/j.annonc.2021.02.024. View

Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241):1907-1918. PMC: 7255743. DOI: 10.1016/S0140-6736(20)31187-9. View

Warner J, Dymshyts D, Reich C, Gurley M, Hochheiser H, Moldwin Z . HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J Biomed Inform. 2019; 96:103239. PMC: 6697579. DOI: 10.1016/j.jbi.2019.103239. View

Chung D, Shah G, Devlin S, Ramanathan L, Doddi S, Pessin M . Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov. 2021; 2(6):568-576. PMC: 8580617. DOI: 10.1158/2643-3230.BCD-21-0139. View

Thompson M, Henderson J, Shah P, Rubinstein S, Joyner M, Choueiri T . Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021; . PMC: 8377563. DOI: 10.1001/jamaoncol.2021.1799. View

Vijenthira A, Gong I, Fox T, Booth S, Cook G, Fattizzo B . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136(25):2881-2892. PMC: 7746126. DOI: 10.1182/blood.2020008824. View

Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F . Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020; 7(10):e737-e745. PMC: 7426107. DOI: 10.1016/S2352-3026(20)30251-9. View

Rubinstein S, Steinharter J, Warner J, Rini B, Peters S, Choueiri T . The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. Cancer Cell. 2020; 37(6):738-741. PMC: 7188629. DOI: 10.1016/j.ccell.2020.04.018. View

10.

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R . Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7):894-901. PMC: 7270947. DOI: 10.1016/j.annonc.2020.03.296. View

11.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

12.

Elkrief A, Wu J, Jani C, Enriquez K, Glover M, Shah M . Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discov. 2021; 12(2):303-330. PMC: 8831477. DOI: 10.1158/2159-8290.CD-21-1368. View

13.

Kurokawa T, Hase M, Tokuman N, Yoshida T . Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol. 2010; 29(1):5-9. DOI: 10.1002/hon.947. View

14.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

15.

Bonuomo V, Ferrarini I, DellEva M, Sbisa E, Krampera M, Visco C . COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World J Virol. 2021; 10(6):312-325. PMC: 8641038. DOI: 10.5501/wjv.v10.i6.312. View

16.

Brar G, Pinheiro L, Shusterman M, Swed B, Reshetnyak E, Soroka O . COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. J Clin Oncol. 2020; 38(33):3914-3924. PMC: 7676890. DOI: 10.1200/JCO.20.01580. View

17.

Wood W, Neuberg D, Thompson J, Tallman M, Sekeres M, Sehn L . Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020; 4(23):5966-5975. PMC: 7724912. DOI: 10.1182/bloodadvances.2020003170. View

18.

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

19.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

20.

Mato A, Roeker L, Lamanna N, Allan J, Leslie L, Pagel J . Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020; 136(10):1134-1143. PMC: 7472711. DOI: 10.1182/blood.2020006965. View